FDA shifts 60-year default: One pivotal clinical trial is now the default for drug approval – replacing the two-trial requirement
GNQ INSILICO – COMPETITIVE ADVANTAGE Where Causal Biology Meets Clinical Precision GNQ’s pathway-driven platform doesn’t just predict – it also explains. By modeling the biological mechanisms that determine patient outcomes, we deliver what the new regulatory era demands: one definitive trial, designed right from the start. GNQ INSILICO – COMPETITIVE ADVANTAGE Improved Prediction Accuracy […]